Veracyte Stock

Veracyte P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Veracyte (VCYT) as of Aug 7, 2026 is 19.18. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 34.82 — a change of -44.91% (lower).

P/CF

19.18

YoY

-44.91%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Veracyte is 2026 19.18 . P/CF (Price-to-Cash-Flow Ratio) of Veracyte was 2025 34.82 . It decreases by -44.91% lower compared to the previous year.
Access this data via the Eulerpool API

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veracyte stock

P/CF (Price-to-Cash-Flow Ratio) of Veracyte is 19.18 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Veracyte changed from 34.82 to 19.18, representing a -44.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Veracyte since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Veracyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Veracyte

All Key Metrics — Veracyte